アレルギーと神経ペプチド　Vol.1　2005年

出版社： 日本医学館
著者：
発行日： 2005-03-03
分野： 臨床医学：内科  >  アレルギー
ISBN： 489044582X
電子書籍版： 2005-03-03
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

1,100 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

550 円(税込)

購入する

商品紹介

本誌創刊号では、神経ペプチド研究の展開の速い皮膚科領域から、この分野では第一人者である大阪大学の片山一朗教授による“皮膚科領域におけるサブスタンスPの産生機構と役割”を掲載。アレルギーと神経ペプチド研究会編集。

目次

  • アレルギーと神経ペプチド　Vol.1　2005年

    ―目次―

    本誌の創刊に寄せて

    特集“皮膚科領域におけるサブスタンスP”
    　PRESENTATION
    　　皮膚科領域におけるサブスタンスPの産生機構と役割
    　COMMENT & IMPRESSION
    　　サブスタンスPのautocrine機構
    　　皮膚アレルギー性炎症とサブスタンスP
    　　アレルギー性鼻炎の研究の立場から
    　　サブスタンスPの産生機構と役割

    文献紹介
    　1．アトピー性皮膚炎患者の末梢血単核球細胞に対する
    　　　　サブスタンスPの影響（Kim KH et al.）
    　2．ブラディキニンはアレルギー性鼻炎患者の
    　　　　CXCケモカイン受容体であるCXCR1とCXCR2の発現を
    　　　　増加させる（Eddleston J et al.）
    　3．喘息患者におけるNKA誘発性気道収縮に対する
    　　　　NK1/NK2拮抗薬DNK333の有効性（Joos GF et al.）
    　4．マウスではストレスによって気道炎症が増悪し，
    　　　　気道反応性が亢進する機序としてneurokinin-1受容体が
    　　　　関与している（Joachim RA et al.）

    REVIEW & TOPICS
    　神経ペプチドによる皮膚の炎症反応
    　神経ペプチドと新しい気管支喘息治療薬
    　抗アレルギー薬塩酸オロパタジンの
    　　神経原性炎症に対する抑制作用

    EDUCATIONAL LECTURE
    サブスタンスPとタキキニンファミリー

    WAVE OF MEDICINE
    “ニューロペプタイド研究会”のあゆみ

    DRUG-REPORT
    　神経原性炎症を制御する抗アレルギー薬−その近未来像

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 "皮膚科領域におけるサブスタンスP"

P.17 掲載の参考文献
1) Shannon CJ:J Allergy Clin Immunol 111:1293, 2003.
 
2) Joos GF:Eur RespirJ 23:76, 2004.
PubMed

REVIEW&TOPICS

P.30 掲載の参考文献
1) Barnes PJ, Baraniuk J, Belvisi MG:Neuropeptides in the respiratory tract. art H. Am Rev Respir Dis 1991:144:1391-1399.
 
2) Weihe E, Hartshchuh W:Multiple peptides in cutaneous nerves:regulators under physiological conditions and a pathogenetic role in skin disease? Semin Dermatol 1988, 7:284-300.
 
3) Jancso N, Jancso-Gabor A, Szolcsanyi J:Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J harmacol 1967, 31:138-151.
PubMed
4) Matsuda H, Kawakita K, Kiso Y, Nakano T, Kitamura Y:Substance induces granulocyte infiltration through degranulation of mast cells. J Immunol 1989, 142:927-931.
PubMed
5) Iwamoto I, Tomoe S, Tomioka H, Yoshida S:Leukotriene B4 mediates substance-induced granulocyte infiltration into mouse skin. Comparison with antigen-induced granulocyte infiltration. J Immunol 1993, 151:2116-2123.
PubMed
6) Bauer O, Razin E:Mast Cell-Nerve Interactions. News hysiol Sci 2000, 15:213-218.
PubMed
7) Fewtrell CM, Foreman JC, Jordan CC, Oehme, Renner H, Stewart JM:The effects of substance on histamine and 5-hydroxy-tryptamine release in the rat. J hysiol 1982, 330:393-411.
 
8) Soter NA, Lewis RA, Corey EJ, Austen KF:Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 1983, 80:115-119.
PubMed
9) Robinson C, Benyon C, Holgate ST, Church MK:The IgE-and calcium-dependent release of eicosanoids and histamine from human purified cutaneous mast cells. J Invest Dermatol 1989, 93:397-404.
PubMed
10) Morita E, Hiragun T, Tanaka T et al.:Mouse bone marrow-derived mast cells acquire responsiveness to substance after co-culture with 3T3 fibroblasts in the presence of stem cells factor. Allergology international 1998, 47:205-212.
 
11) 岡部 勉, 秀 道広, 山本昇壯:マウス骨髄由来培養肥満細胞からのヒスタミン, LTB4遊離におけるMAPキナーゼの役割(会議録). アレルギー 1999, 48:968.
 
12) Furutani K, Koro O, Hide M, Yamamoto S:Substance-and antigen-induced release of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by different mechanisms in vitro. Arch Dermatol Res 1999, 291:466-473.
PubMed
13) 高路 修, 古谷喜義, 山本昇壯. アトピー性皮膚炎とタキキニン. アレルギー科 2000, 9:334-339.
 
14) Koro O, Furutani K, Hide M, Yamada S, Yamamoto S:Chemical mediators in atopic dermatitis:involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999, 103:663-670.
PubMed
15) Okabe T, Hide M, Koro O, Nimi N, Yamamoto S:The release of leukotriene B4 from human skin in response to substance:evidence for the functional heterogeneity of human skin mast cells among individuals. Clin Exp Immunol 2001, 124:150-156.
PubMed
16) Okabe T, Hide M, Koro O, Yamamoto S:Substance induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur J harmacol 2000, 398:309-315.
PubMed
17) van der Kleij HP, Ma D, Redegeld FA, Kraneveid AD, Nijkamp FP, Bienenstock J:Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol 2003, 171:2074-2079.
 
18) 豊田雅彦:アトピー性皮膚炎のかゆみ対策. 日本医師会雑誌 2004, 132:1523-1527.
 
19) 豊田雅彦:タクロリムス軟膏によるアトピー性皮膚炎の止痒機序-皮膚神経系因子の観点から. 臨床皮膚科 2003, 57:45-50.
 
P.34 掲載の参考文献
1) Barnes PJ:Respiratory pharmacology. Textbook of respiratory medicine, 2ed, ED by Murray JF, Nadel JA, Saunders, 1994, p251-322.
 
2) 吉原重美:神経ペプチド. 日本小児呼吸器疾患学会誌 1997, 8:8-19.
 
3) Ricciardolo FLM, Yoshihara S, Geppetti P et al.:Role of kinins in anaphylactic-induced bronchoconstriction mediated by tachykinins in guinea pigs. Br. J. Pharmacol 1994, 113:508-512.
 
4) Yoshihara S, Ricciardolo FLM, Nadel JA et al.:Corticotropin releasing factor inhibits antigen-induced plasma extravasation in airways. Eur. J. Pharmacol 1995, 280:113-118.
 
5) Yoshihara S, Geppetti P, Nadel JA et al:Plasma extravasation in the rat trachea induced by cold air is mediated by tachykinin release from sensory nerves. Am J Respir Crit Care Med 1995, 151:1011-1017.
PubMed
6) Yoshihara S, Gcppctti P, Nadcl JA et al.:Tachykinins mediate the potentiation of antigen-induced bronchoconstriction by cold air in guinea pigs. J Allergy Clin Immunol 1996, 97:756-760.
 
7) Yoshihara S, Geppetti P, Nadel JA et al:Cold air-induced bronchoconstriction is mediated by tachykinin and kinin release in guinea pigs. Eur J Pharmacol 1996, 296:291-296.
PubMed
8) Watanabe M, Yoshihara S, Arisaka O et al.:Cigarette smokeinduced plasma extravasation is inhibited by CP99. 994, but not HOE140. Biomed Res 1998, 19:309-314.
 
9) Ricciardolo FLM, Yoshihara S. Geppetti P et al.:Evidence for reduction ofbradykinin-induced bronchoconstriction in guinea-pigs by release of nitric oxide. Br J Pharmacol 1994, 113:1147-1152.
 
10) Ichinose M, Nakajima T, Takishima T et al.:Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992, 340:1248-1251.
 
11) Watanabe M, Yoshihara S, Arisaka O et al.:Effects of the orally active non-peptide bradykinin B2 receptor antagonist, FR 173657, on plasma extravasation in guinea pig airways. Eur J Pharmacol 1999, 367:373-378.
PubMed
12) Yoshihara S, Nadel JA, Geppetti P et al.:Endogenous nitric oxide inhibits bronchoconstriction induced by cold-air inhalation in guinea pigs-Role of kinins-. Am J Resp Crit Care Med 1998, 17:547-552.
 
13) Yoshihara S, Yamada Y, Arisaka O:Airway inflammation and epithelial damage in childhood asthma. Current Advances in Pediatric Asthma and Other Allergic Diseases, Edited by A. Morikawa, Jomo Newspaper, Co. Ltd. p45-48, 2002.
 
14) Asai H, Yoshihara S, Ichimura T, Yanaihara N et al:Changes in substance P and vasoactive intestinal polypeptide levels in the respiratory tract of aging guinea pigs. Biomed Res 1991, 12:41-46.
 
15) Ono M, Abe T, Yoshihara S et al.:Nedocromil Sodium Inhibits Hypertonic Saline-induced Plasma Extravasation in Guinea Pig Airways. Biomed Res 1999, 20:233-238.
 
16) Yoshihara S, Ono M, Arisaka O et al.:Nedocromil sodium inhibits bradykinin-and antigen-induced plasma extravasation in guinea pigs airways. Biomed Res 2001, 22:19-24.
 
17) Yoshihara S, Abe T, Ichimura T et al:Skin stimulation with cold water inhibits capsaicin-induced cough and decreases substance P-like immunoreactivity in guinea pig lungs. Biomed Res 1996, 17:271-278.
 
18) Abe T, Yoshihara S, Ichimura T et al.:Skin stimulation with cold water inhibits capsaicin-induced plasma extravasation in guinea-pig airways. Biomed Res 1997, 18:75-79.
 
19) Yoshihara S, Morimoto H, Yamada Y et al.:Cannabinoid receptor agonists inhibit sensory nerves activation in guinea-pig airways. Am J Respir Crit Care Med 2004, 170:941-946.
PubMed
20) Miura M, Inoue H, Takishima T et al.:Effect of nonadrenergic noncholinergic inhibitory nerve stimulation on the allergic reaction in cat airways. Am Rev Respir Dis 1990, 141, 29-32.
PubMed
21) Linden A, Yoshihara S, Nadel JA et al.:Inhibition of bronchoconstriction by pituitary adennylate cyclase activating polypeptide(PACAP1-27) in guinea pigs in vivo. Br J Pharmacol 1995, 115:913-916.
 
22) Linden A, Yoshihara S, Nadel J A et al.:PACAP1-38 as aninhaled bronchodilator in guinea pigs in vivo. Peptides 1998, 19:93-98.
 
23) Kashimoto K, Yoshihara S, Ichimura T et al.:Structure-activity relationship studies of PACAP 1-27 and VIP analogues. Ann NY Acad Sci 1996, 805:505-510.
 
24) Yoshihara S, Linden A, Nadel JA et al:Anovel PACAP 1-27 analogue causes sustained smooth muscle relaxation in guinea pigtrachea. Ann NY Acad Sci 1996, 805:536-542.
 
25) Yamada Y, Yoshihara S, Ichimura T et al.:Sustained relaxant action of [Arg, 15, 20, 21, Leu17] -PACAP1-27-NH2 on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro. Biomed Res 1998, 19:39-44.
 
26) Yoshihara S, Linden A, Nadel JA et al.:Long lasting smooth muscle relaxation by a novel PACAP analogue in guinea pig and primate airways in vitro. Brit J Pharmacol 1997, 121:1730-1734.
 
27) Linden A, Yoshihara S, Nadel JA et al.:Bronchodilation by pituitary adenylate cyclase-activating peptide and related peptides. Eur Respir J 1999, 14:443-451.
PubMed
28) Yoshihara S, Yamada Y, Arisaka O et al.:Long Lasting smooth muscle relaxation by a novel PACAP analogue in human bronchL Regul Pept 2004, 123, 161-165.
 
29) Okazawa A, Yoshihara S, Linden A et aL:Effect of a novel PACAPI-27 analogue on muscarinic airway responsiveness in guinea-pigs in vivo. Eur Respir J 1998, 12-1062-1066.
 
30) Yoshihara S, Linden A, Watanabe S et al.:Anovel long-acting VIP analogein the guinea pig trachea in vitro. Peptides 1998, 19:593-597.
 
31) Sergejeva S, Yoshihara S, Linden A et al.:Synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul. Pept 2004, 117:149-154.
PubMed
32) 吉原重美, 有阪 治:気管支喘息と自律神経. 小児内科 36, 535-540, 2004.
 
P.36 掲載の参考文献
1) Ikemura T, Okamura K, Sasaki Y, Ishii H, Ohmori K:KW-4679-induced inhibition of tachykininergic contraction in the guinea pig brochi by prejunctional inhibition of peripheral sensory nerve. Br JPharmacol 117:967-973, 1996.
 
2) Ikemura T, Sasaki Y, Ishii H, Ohmori K:Inhibitory effect of KW-4679, an anti-allergic drug, on tachykinin-mediated airway responseinduced by electrical stimulation in guinea pigs. Jpn J Pharmacol 71:179-182, 1996.
 
3) Hayashi K, Sato H, Kaise T, Ohmori K:Roles of mast cells and sensory nerves in cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rats. Eur J Pharmaco1425:219-227, 2001.
PubMed
4) Hayashi K, Kaise T, Ohmori K:Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rats. Jpn J Pharmacol 87:167-170, 2001.
PubMed
5) Sugimoto Y, Ishihara S, Kayasuga R, Kamei C:Evaluation of olopatadine on scratching and sneezing responses using histamine H1 receptor deficient mice. Jpn J Allergol 52:944, (text in Japanese), 2003.
 
6) Sugimoto Y, Ogasawara R, Watanabe T, Kamei C:Inhibitory effect of olopatadine on nasal rubbing induced by capsaicin in histamine H1 receptor-deficient and mast cell-deficient mice. J Pharmacol Sci 94:203P, 2004.
 
7) Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M:Nerve growth factor and substance P are useful markers of disease activity in atopic dermatitis. Br J Dermatol 147:71-79, 2002.
PubMed
8) Tamura T, Matsubara M, Takada C, Hasegawa K, Suzuki K, Ohmori K, Karasawa A:Effects of olopatadine hydrochloride, an antihistaminic drug, on skin inflammation induced by repeated topical application of oxazolone in mice. Br J Dermatol 151, 1133-1142, 2004.
PubMed

EDUCATIONAL LECTURE

P.42 掲載の参考文献
1) von Euler US, Gaddum JH:An unidentified depressor substance in certain tissue extracts. J Physiol 1931, 72:74-87.
 
2) Lembeck F:Zur Frage der zentralen Ubertragung afferenter Impulse. III. Mitteilung. Das Vorkommen und die Bedeutung der Substanz P in den dorsalen Wurzeln des Ruckenmarks. Arch Exp Path u Pharmakol 1953, 219:197-213.
 
3) Chang MM, Leeman SE, Niall, HD:Amino-acid sequence of substance P. Nature-New Biol 1971, 232:86-87.
PubMed
4) Konishi S, Otsuka M:Excitatory action of hypothalamic substance Pon spinal motoneurones of newborn rats. Nature 1974, 252:734-735.
 
5) Kimura S, Okada M, Sugita Y, Kanazawa I, Munekata E:Novel neuropeptides, Neurokinin α and β, isolated from porcine spinal cord. Proc Jpn Acad 1983, 59B:101-104.
 
6) Kangawa K, Minamino N, Fukuda A, Matsuo H. Neuromedin K:a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun 1983, 114:533-540.
PubMed
7) Patacchini R, Lecci A, Holzer P, Maggi CA:Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004, 25:1-3.
PubMed
8) Nawa H, Kotani H, Nakanishi S:Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature 1984, 312:729-734.
PubMed
9) Suzuki H, Otsuka M:Isolated CNS preparations for studies on substance P and other neurotransmitters. "Methods in neurotransmitter and neuropeptide research"(Parvez SH, Naoi M, Nagatsu T, Parvez S, eds), 1993, Elsevier, Amsterdam, The Netherlands, p443-455.
 
10) Takahashi T, Otsuka M:Regional distribution of substance P in the spinal cord and nerve roots of the cat and the effect of dorsalroot section. Brain Res 1975, 87:1-11.
 
11) DiFiglia M, Aronin N, Leeman SE:Light microscopic and ultrastructural localization of immunoreactive substance P in the dorsal horn of monkey spinal cord. Neuroscience 1982, 7:1127-1139.
PubMed
12) McLeod AL, Krause JE, Cuello AC, Ribeiro-da-Silva A:Preferential synaptic relationships between substance Pimmunoreactive boutons and neurokinin 1 receptor sites in the rat spinal cord. Proc Natl Acad Sci USA 1998, 95:15775-15780.
PubMed
13) Otsuka M, Konishi S:Release of substance P-1ike immunoreactivity from isolated spinal cord of newborn rat. Nature 1976, 264:83-84.
 
14) Nussbaumer J-C, Yanagisawa M, Otsuka M:Pharmacological properties of a C-fibre response evoked by saphenous nerve stimulation in an isolated spinal cord-nerve preparation of the newborn rat. Br J Pharmacol 1989, 98:373-382.
 
15) Suzuki H, Yoshioka K, Yanagisawa M, Urayama O, Kurihara T, Hosoki R, Saito K, Otsuka M:lnvolvement of enzymatic degradation in the inactivation of tachykinin neurotransmitters in neonatal rat spinal cord. Br J Pharmacol 1994, 113:310-316.
PubMed
16) Masu Y, Nakayama K, Tamaki H, Harada Y, Kuno M, Nakanishi S:cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature 1987, 329:836-838.
PubMed
17) Nakanishi S:Mammalian tachykinin receptors. Annu Rev Neurosci 1991, 14:123-136.
PubMed
18) Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S:Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 1992, 267:2437-2442.
 
19) Fong TM, Anderson SA, Yu H, Huang RR, Strader CD:Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 1992, 41:24-30.
PubMed
20) Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N:Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994, 347:249-274.
 
21) Ding Y-Q, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N:Localization of the neuromedin K receptor(NK3) in the central nervous system of the rat J Comp Neurol 1996, 364:290-310.
 
22) Suzuki H, Yoshioka K, Maehara T, Hagan RM, Nakanishi S, Otsuka M:Pharmacological characteristics of tachykinin receptors mediating acetylcholine release from neonatal rat spinal cord. Eur J Pharmacol 1993, 241:105-110.
PubMed
23) Takano K, Yasufuku-Takano J, Kozasa T, Singer WD, Nakajima S, Nakajima Y:Gq/11 and PLC-β1 mediate the substance P-induced inhibition of an inward rectifier K+ channel in brain neurons. J Neurophysiol 1996, 76:2131-2136.
 
24) Shapiro MS, Hille B:Substance P and somatostatin inhibit calcium channels in rat sympathetic neurons via different G protein pathways. Neuron 1993, 10:11-20.
PubMed
25) Zhao FY, Saito K, Yoshioka K, Guo JZ, Murakoshi T, Konishi S, Otsuka M:Tachykininergic synaptic transmission in the coeliac gangllon of the guinea-pig. Br J Pharmacol 1996, 118:2059-2066.
PubMed
26) Whittle BJR, Lopez-Belmonte J, Rees DD:Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol 1989, 98:646-652.
 
27) Otsuka M, Yoshioka K:Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993, 73:229-308.
PubMed
28) Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y:Gprotein activation:a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 1990, 11:358-362.
 
29) Maehara T, Suzuki H, Yoshioka K, Otsuka M:Characteristics of substance P-evoked release of amino acids from neonatal rat spinal cord. Neuroscience 1995, 68:577-584.
PubMed
30) Snider RM, Constantine JW, Lowe III JA, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, Hess H-J:Apotent nonpeptide antagonist of the substance P(NKI) receptor. Science 1991, 251:435-437.
 
31) Fong TM, Yu H, Strader CD:Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96, 345 and RP67580. J Biol Chem 1992, 267:25668-25671.
PubMed
32) Bevan S, Szolcsanyi J:Sensory neuron-specific actions of capsaicin:mechanisms and applications. Trends Pharmacol Sci 1990, 11:330-333.
 
33) Guo JZ, Yoshioka K, Yanagisawa M, Hosoki R, Hagan RM, Otsuka M:Depression of primary afferent-evoked responses by GR71251 in the isolated spinal cord of the neonatal rat. Br J Pharmacol 1993, 110:1142-1148.
PubMed
34) Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D:The capsaicin receptor:a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
PubMed
35) Turner AJ, Matsas R, Kenny AJ:Are there neuropeptide-specific peptidases? Biochem Pharmacol 1985, 34:1347-1356.
PubMed
36) Toide K, Okamiya K, Iwamoto Y, Kato T:Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, 0n prolyl endopeptidase activity and substance P-and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem 1995, 65:234-240.
 
37) Damas J, Bourdon V, Li6geois JF, Simmons WH:Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase. Naunyn Schmiedebergs Arch Pharmacol 1996, 354:662-669.
 
38) Bertrand C, Geppetti P:Tachykinin and kinin receptor antagonists:therapeutic perspectives in allergic airway disease. Trends Pharmacol Sci 1996, 17:255-259.
PubMed
39) Kohrogi H, Yamaguchi T, Kawano O, Honda I, Ando M, Araki S:Inhibition of neutral endopeptidase potentiates bronchial contraction induced by immune response in guinea pigs in vitro. Am Rev Respir Dis 1991, 144:636-641.
PubMed
40) Ahmad S, Wang L, Ward PE:Dipeptidyl (amino) peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 1992, 260:1257-1261
 
41) Snider WD, McMahon SB:Tackling pain at the source:new ideas about nociceptors. Neuron 1998, 20:629-632.
PubMed
42) Guo A, Vulchanova L, Wang J, Li X, Elde R:Immunocytochemical localization of the vanilloid receptor 1(VR1):relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999, 11:946-958.
 
43) McLeod AL, Ritchie J, Cuello AC, Julien J-P, Ribeiro-da-Silva A, Henry JL:Transgenic mice over-expressing substance P exhibit allodynia and hyperalgesia which are reversed by substance P and N-methyl-D-aspartate receptor antagonists. Neuroscience 1999, 89:891-899.
 
44) Malcanglo M, Ramer MS, Boucher TJ, McMahon SB:Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord. Eur J Neurosci 2000, 12:139-144.
 
45) De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJH, Laird JMA, Belmonte C, Cervero F, Hunt SP:Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998, 392:394-397.
 
46) Rupniak NMJ, Kramer MS:Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor(NK, )antagonists. Trends Pharmacol Sci 1999, 20:485-490.
 
47) Hill R:NK, (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci 2000, 21:244-246.
 
48) Campbell EA, Gentry C, Patel S, Kidd B, Cruwys S, Fox AJ, Urban L:Oral anti-hyperalgesic and anti-infiammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. Pain 2000, 87:253-263.
 
49) Hargreaves R:Imaging substance P receptors(NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002, 63 Suppl 11:18-24.
 
50) Kincy-Cain T, Bost KL:Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance Pantagonist, spantide II. J Immunol 1996, 157:255-264.
 
51) Metwali A, Blum AM, Elliott DE, Setiawan T, Weinstock JV. Cutting edge:hemokinin has substance P-like function and expression in inflammation. J Immunol 2004, 172:6528-6532.
PubMed
52) Blum AM, Metwali A, Kim-Miller M, Li J, Qadir K, Elliott DE, Lu B, Fabry Z, Gerard N, Weinstock JV:The substance P receptor is necessary for a normal granulomatous response in murine schistosomiasis mansoni. J Immunol 1999. 162:6080-6085.
PubMed
53) Mantyh CR, Gates TS, Zimmerman RP, Welton ML, Passaro EP Jr, Vigna SR. Maggio JE, Kruger L, Mantyh PW:Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci USA 1988, 85:3235-3239.
PubMed
54) Goode T, O'Connell J, Anton P, Wong H, Reeve J, O'Sullivan GC, Collins JK, Shanahan F:Neurokinin-1 receptor expression in inflammatory bowel disease:molecular quantitation and localisation. Gut 2000, 47:387-396.
PubMed
55) Sanger GJ:Neurokinin NKI and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. BrJPharmacol 2004, 141:1303-1312.
 
56) de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ:The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy:a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004, 40:403-410.
PubMed
57) Aguiar MS, Brandao ML:Effects of microinjections of theneuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol Behav 1996, 60:1183-1186.
PubMed
58) Culman J, Unger T:Central tachykinins:mediators of defence reaction and stress reactions. Can J Physiol Pharmacol 1995, 731 885-891.
 
59) Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J et al.:Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
PubMed
60) Brodin E, Rosen A, Schott E, Brodin K:Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides 1994, 26:253-260.
PubMed
61) Enserink M:Can the placebo be the cure? Science 1999, 284:238-240.
PubMed
62) Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munlack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y:Demonstration of the efficacy and safety of a novel substance P(NK1) receptorantagonist in major depression. Neuropsychopharmacology 2004, 29:385-392.
 
63) Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ:Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat lmmunol 2000, 1:392-397.
 
64) Kurtz MM, Wang R, Clements MK, Cascieri MA, Austin CP, Cunningham BR, Chicchi GG, Liu Q:Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 2002, 296:205-212.
PubMed
65) Page NM, Bell NJ, Gardiner SM, Manyonda IT, Brayley KJ, Strange PG, Lowry PJ:Characterization of the endokinins:human tachykinins with cardiovascular activity. Proc Natl Acad Sci USA 2003, 100:6245-6250.
PubMed

WAVE OF MEDICINE

P.48 掲載の参考文献
1) 徳山研一, 梅野英輔, 勝沼俊雄, 亀田 誠, 坂本龍雄, 濱崎雄平, 増田敬, 吉原 重美:小児気管支喘息に対する吸入抗コリン薬の使用状況 -アレルギー専門小児科医を対象とした質問表による調査-. 日本小児アレルギー学会雑誌 18(3):270-278, 2004.
 

DRUG-REPORT

P.53 掲載の参考文献
1) O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F:The role of substance P in inflammatory disease. J Cell Physioi 2004, 201:167-180.
 
2) Pennefather JN. Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA:Tachykinins and tachykinin receptors:a growing family. Life Sci 2004, 74:1445-1463.
PubMed
3) Joos GF, Pauwels RA:Pro-inflammatory effects of substance P:new perspectives for the treatnlent of airway diseases? Trends Pharmacol Sci 2000, 21:131-133.
PubMed
4) Groneberg DA, Quarcoo D, Frossard N, Fischer A:Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 2004, 59:1139-1152.
PubMed
5) Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M:Nerve growth factor and substance P are useful markers of discase activity in atopic dermatitis. Br J Dermatol 2002, 147:71-79.
 
6) Foreman JC, Piotrowski W:Peptides and histamine release. J Allergy Clin Immunol 1984, 74:127-131.
PubMed
7) Smith CH, Barker JNWL, Morris RW, MacDonald DM, Lee TH:Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocyic infirtration in human skin. J Immunol 1993, 151:3274-3282.
PubMed
8) Carolan ED, Casale T:Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers. J Allergy Clin Immunol 1993, 92:589-598.
 
9) Payan DG, Brewster DR, Goetzl EJ:Specific stimulation of human T lymphocytes by substance P. J Immunol 1983, 131:1613-1615.
 
10) Calvo CF, Chavanel G, Senik A:Substance P enhances in activated human T cells. J Immunol 1992, 148:3498-3504.
 
11) Aebischer I, Stampfll MR, Miescher S, Horn M, Zurcher AW, Stadler BM:Neuropeptides accentuate interleukin-4 induced human immunoglobukin E synthesis in vitro. Exp Dermatol 1996, 5:38-44.
 
12) Maggi CA:The effects of tachykinis on inflammatory and ilnmune cells. Regul Pept 1997, 70:75-90.
 
13) Theriault E, Otsuka M, Jessell T:Capsaicin-evoked release of substance P from primary sensory neurolls. Brain Res 1979, 170:209-213.
PubMed
14) Kress M, Zeilhofer HU:Capsaicin, protons and heat:new excitement about nociceptors. Trends Pharmacol Sci 1999, 20:112-118.
PubMed
15) Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D:The capsaicin receptor:a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
PubMed
16) Yaksh TL, Farb DH. Leeman SE, Jessell TM:Intrathecal capsaicin depletes substance P in the rat spinal cord and produces prolonged thermal analgesia. Science 1979, 206:481-483.
 
17) Tramontana M, Santicioli P, Giuliani S, Catalioto RM, Lecci A, Carini F, Maggi CA:Role of tachykinins in sephadex-induccd airway hyperreactivity and inflammation in guinea pigs. Eur Pharmacol 2002, 439:149-158.
 
18) Tiberio IF. Turco GM, Leick-Maldonado EA, Sakae RS, Paiva SO, do Patrocinio M, Warth TN, Lapae Silva JR, Saldiva PH, Martins MA:Effects of neurokinin depletion on airway inflammation induced by chronic antigen expostlre. Am J Respir Crit Care Med 1997, 155:1739-1747.
 
19) Dray A:Mechanism of action of capsaicin-1ike molecules on sensory neurons. Life Sci 1992, 51:1759-1765.
 
20) Szolcsanyi J, Szallasi A, Szallasi Z, Joo F, Blumberg PM:Resiniferatoxin:an ultrapotent selective Inodulator of capsaicil1-sensitive primary afferent neurons. J Pharmacol Exp Ther 1990, 255:923-928.
PubMed
21) Ichinose M, Barnes PJ:Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo. Eur J Pharmacol 1989, 174:49-55.
PubMed
22) Fox AJ, Barnes PJ, Venkatesan P, Belvisi MG:Activation of large conductance potassium channel:inhibits the afferent and efferent function of airway sensory nerves in the guinea pig. J Clin lnvest 1997, 99:513-519.
 
23) Matran R, Martling CR, Lundberg JM:bhibition of cholinergic and non-adrenergic, non-cholinergic bronchoconstriction in the guinea pig mediated by neuropeptide Y and alpha 2-drenoceptors and opiate receptors. Eur J Pharmacol 1989, 163:15-23.
PubMed
24) Verledcn GM, Belvisi MG, Rabe KF, Miura M. Barnes PJ:Beta 2-adrenoceptor agonists inhibit NANC neural bronchoconstrictor responses in vitro. J Appl Physiol 1993, 74:1195-1199.
 
25) Undem BJ, Meeker SN, Chen J:Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J Pharmacol Exp Ther 1994, 271:811-817.
PubMed
26) Verleden GM, Belvisi MG, Stretton CD, Barnes PJ:Nedocromil sodium modulates nonadrenergic, noncholinergic broncho-constrictor nerves in guinea pig airways in vitro. Am Rev Respir Dis 1991, 143:114-118.
 
27) Ikemura T, Okarmura K, Sasaki Y, Ishi H, Ohmori K:KW-4679-induced inhibition of tachykininergic contraction in the guinea-pig bronchi by prejunctional inhibition of peripheral sensory nerves. Br J Pharmacol 1996, 117:967-973.
PubMed
28) Verleden GM, Pype JL, Demedts MM:Ketotifen modulates noncholinergic contraction in guinea pig airways in vitro by a prejunctional nonhistamine receptor. J Allergy Clin Immunol 1994, 94:207-214.
PubMed
29) Walter L, Stella N:Cannabinoids and neuroinflammation. Br J Pharmacol 2004, 141:775-785.
PubMed
30) Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ, Scott RH:Actions of cannabinoid receptor ligands on rat cultured sensory neurones:implications for antinociception. Neuropharmacology 2001, 40:221-232.
PubMed
31) Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D:Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000, 408:96-101.
PubMed
32) Morita K, Kamei J. Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist. Eur J Pharmacol 2003, 474:269-272.
PubMed
33) Lever IJ, Malcangio M:CBI receptor antagonist SRI41716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord. Br J Pharmacol 2002, 135:21-24.
 
34) Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V:Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004, 20:2311-2320.
PubMed
35) Yoshihara S, Morimoto H, Yamada Y, Abe T, Arisaka O:Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways. Am J Respir Crit Care Med 2004, 170:941-946.
PubMed
36) Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F:Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2002, 97:3090-3098.
 
37) Giardina GA, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S, Foley JJ, Vecchietti V, Hay DW:Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of(S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide(SB 223412). J Med Chem 1999, 42:1053-1065.
 
38) Oury-Donat F, Carayon P, Thurneyssen O, Pailhon V, Emonds-Alt X, Soubrie P, Le Fur G:Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1995, 274:148-154.
 
39) Giardina GA, Gagliardi S, Martinelli M:Antagonists at the neurokinin receptor-recent patent literature. Drugs 2003, 6:758-772.
PubMed
40) Kraan J, Vink-Klooster H, Postma DS:The NK-2 receptor antagonist SR 48968C dose not improve adenosine hyperrespon-siveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001, 31:274-278.
 
41) Gerspacher M, Lewis C, Ball HA, Howes C, Subramanian N, Ryffel K, Fozard JR:Stereoselective preparation of N-[(R, R)-(E)-1-(3, 4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl] allyl-N-methyl-3, 5-bis(trifluoromethyl) benzamide, a potent and orally active dual neurokinin NK1/NK2 receptor antagonist. J Med Chem 2003, 46:3508-3513.
 
42) Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang JH, Shaw MJ, Cioppa GD, Pauwels RA:Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004, 23:76-81.
PubMed
43) Anthes JC, Chapman RW, Richard C, Eckel S, Corboz M, Hey JA, Femandez X, Greenfeder S, McLeod R, Sehring S, Rizzo C, Crawley Y, Shih NY, Piwinski J, Reichard G, Ting P, Carruthers N, Cuss FM, Billah M, Kreutner W, Egan RW:SCH 206272:a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist. Eur J Pharmacol 2002, 450:191-202.
 

書評

最近チェックした商品履歴

Loading...